Literature DB >> 8020554

Infiltrating T cells from patients with primary Sjögren's syndrome express restricted or unrestricted T cell receptor V beta regions depending on the stage of the disease.

F Legras1, T Martin, A M Knapp, J L Pasquali.   

Abstract

Organ-specific autoimmune diseases are usually considered to be mediated by autoreactive T cells which infiltrate the target tissue. Conceivably, these T cells could represent pathogenic autoreactive cells which recognize their specific antigen (peptide or superantigen) within the pathological tissue. Extensive studies dealing with the clonality of the infiltrating autoreactive cells gave conflicting results both in humans and animals. One possibility for explaining these contradictory data could rely on the stage of the disease when the T cell population is studied. Here, we report on this parameter by analyzing T cell receptor beta-chain variable regions of infiltrating T cells involved during one of the most frequent human organ-specific autoimmune disease, the primary Sjögren's syndrome. Six patients were selected on the basis of the duration of the disease before the biopsy procedure (two early and four late stages) to analyze initial and late T cell waves within the abnormal tissue. Using short-term interleukin-2-stimulated T cells, polymerase chain reactions, Southern and sequence analysis, we conclude that: (a) there is a clear restriction in the V beta usage by the infiltrating T cells only during the early stage of the disease, (b) this V beta restriction is related to a monoclonal T cell expansion, (c) the expanded V beta families are different from one patient to the other, and (d) there is no clear homology in length or amino acid composition in the CDR3 of the analyzed V beta regions. These results could provide an explanation to conflicting results on the V beta restriction usage during autoimmune diseases and could indicate time limitations in anti-V beta treatment. Furthermore, the monoclonal expansion of particular V beta-bearing T cells argues against a role for a superantigen during this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020554     DOI: 10.1002/eji.1830240128

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome.

Authors:  I Matsumoto; K Tsubota; Y Satake; Y Kita; R Matsumura; H Murata; T Namekawa; K Nishioka; I Iwamoto; Y Saitoh; T Sumida
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

Review 2.  The T cell in Sjogren's syndrome: force majeure, not spectateur.

Authors:  Namrata Singh; Philip L Cohen
Journal:  J Autoimmun       Date:  2012-06-17       Impact factor: 7.094

3.  Elevation of serum soluble intercellular adhesion molecule-1 (sICAM-1) and beta-2-microglobulin in Sjögren's syndrome.

Authors:  J Krejsek; R Slezák; O Kopecky; V Derner; C Andrys
Journal:  Clin Rheumatol       Date:  1997-03       Impact factor: 2.980

Review 4.  The important role of T cells and receptor expression in Sjögren's syndrome.

Authors:  A Karabiyik; A B Peck; C Q Nguyen
Journal:  Scand J Immunol       Date:  2013-08       Impact factor: 3.487

5.  Heterogeneity of rearranged T cell receptor V alpha and V beta gene transcripts in synovial fluid T cells of HLA-B27 positive reactive arthritis patients.

Authors:  G M Verjans; V N Klaren; M Leirisalo-Repo; J H Ringrose; H Repo; A Steinle; C E Van Doornik; T E Feltkamp
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

6.  Diverse T cell receptor beta gene usage by infiltrating T cells in the lacrimal glands of Sjögren's syndrome.

Authors:  N Mizushima; H Kohsaka; K Tsubota; I Saito; N Miyasaka
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.